



# UNITED STATES PATENT AND TRADEMARK OFFICE

7

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/006,740	12/05/2001	Alexander MacGregor	23936-176	2553

20985 7590 11/13/2006

FISH & RICHARDSON, PC  
P.O. BOX 1022  
MINNEAPOLIS, MN 55440-1022

EXAMINER
----------

FUBARA, BLESSING M

ART UNIT	PAPER NUMBER
----------	--------------

1618

DATE MAILED: 11/13/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/006,740	MACGREGOR, ALEXANDER	
	<b>Examiner</b>	<b>Art Unit</b>	
	Blessing M. Fubara	1618	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 28 August 2006.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1,3-8,10-12,14-32,34,35 and 37-42 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,3-8,10-12,14-32,34,35 and 37-42 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

### **DETAILED ACTION**

Examiner acknowledges receipt of request for extension of time, amendment and remarks, all filed 8/28/06. Claims 1 and 37-41 are amended. New claim 42 is added. Claims 1, 3-8, 10-12, 14-32, 34, 35 and 37-42 are pending.

#### ***Response to Arguments***

Any rejections that are not reiterated herein are withdrawn.

#### ***Claim Rejections - 35 USC § 102***

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

2. Claims 38 and 39 remain rejected under 35 U.S.C. 102(b) as being anticipated by Dresdner, Jr. et al. (US 5,357,636). Claims 1, 3-5, 7, 8 and 10 are included in this rejection in view of the current amendment. Therefore, claims 1, 3-5, 7, 8, 10, 38 and 39 remain rejected under 35 U.S.C. 102(b) as being anticipated by Dresdner, Jr. et al. (US 5,357,636).

Dresdner, Jr. discloses antiseptic composition comprising antiseptic agents such as povidone iodine, sodium hypochlorite, nonoxynol 9 and chlorhexidine gluconate, sodium dichloroisocyanurate, sodium perborate, to name a few (abstract; column 12, lines 50-67; column 27, lines 39-53; column 27, lines 40-50), surfactant (column 13, line 1), antibiotics (column 27, line 65 to column 28), bicarbonate or peroxide (column 30, line 51 to column 31 line 41), viscosity modifying polymer/agent such as cross-linked polyvinylpyrrolidone and carbopol

(column 35, line 56 to column 36 line 37). The cross-linked polyvinylpyrrolidone is the hydrostatic pressure modulating agent of the claims 38 and 39. Carbopol is cross-linked with allylsucrose or allylpentaerythritol and is the cross-linked hydrodynamic fluid imbibing polymer of claims 38 and 39. Sodium perborate is the expansion source of claims 7, 38 and 39. The antiseptic composition of Dresdner is in a non-liquid form such as a dry solid (abstract; column 20, line 35; column 25, line 42), which meets the limitation that the hydrostatic delivery system is a solid in the claims 28 and 39. The release kinetics of zero order is independent of the concentration of the reactants that would be released and it is ultimately a property/characteristic of the dosage form so that it would be inherent that the non-liquid antiseptic composition of Dresdner would exhibit zero order kinetics for the release of the agent. Claims 3-5 recite the properties/characteristic of the delivery system. The carbonate of this reference is a carbonate source and thus meets the limitation of claims 7, 8 and 10. The teaching of Dresdner, Jr. meets the limitations of the claims.

***Response to Arguments***

3. Applicant's arguments filed 8/28/06 have been fully considered but they are not persuasive.

Applicant, while recognizing that Dresdner discloses antiseptic composition in non-liquid form, such as dry solid, with the composition comprising CARBOPOL 934 (allylsucrose or allylpentaerythritol crosslinked acrylic polymer) or cross-linked polyvinylpyrrolidone or mixture thereof (see applicant's remarks at page 13, third full paragraph and lines 1 and 2 of page 14 of the remarks), states that Dresdner does not disclose a hydrostatic delivery system that includes a homogeneous mixture of an agent of interest and a

Art Unit: 1618

hydrostatic couple in the form of solid compact and from where the agent of interest is released with zero order or near zero order release kinetics when the hydrostatic delivery system comes in contact with an external fluid.

**Response:**

Claims 38 and 39 are directed to delivery systems, in the form of solid, that comprise one or more than one cross-linked hydrodynamic fluid imbibing polymer, one or more than one cross-linked hydrostatic pressure modulating agent and an expansion source that can be sodium percarbonate or sodium perborate monohydrate or anhydrous sodium perborate or .... An agent being released in a zero order or near zero order controlled release is a property/characteristic of the dosage. The cross-linked polyvinylpyrrolidone is the hydrostatic pressure modulating agent of the claims 38 and 39. Carbopol is cross-linked with allylsucrose or allylpentaerythritol and is the cross-linked hydrodynamic fluid imbibing polymer of claims 38 and 39. Sodium perborate is the expansion source of claims 38 and 39. Thus, as recognized by applicant, Dresdner discloses the composition of claims 38 and 39 and therefore, the Dresdner composition would inherently have that property of zero order kinetics where the release is not dependent on the concentration of the agent.

***Claim Rejections - 35 USC § 103***

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1618

5. Claims 1, 3-8, 10-12, 14-32, 34, 35, 40 and 41 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Rork et al. (US 5,582,838) in view of Conte et al. (US 5,780,057).

Rork discloses a tablet formulation (column 7, lines 21-42) comprising pharmaceutically active ingredients such as antimicrobials, local anesthetic, analgesics and anti-inflammatory agents (column 6, lines 18, 20, 24 and 18), excipients such as lactose, magnesium stearate, polyvinylpyrrolidone and dyes (column 8, lines 13-25), CARBOPOL polymer (column 8, lines 45-65) and carbonate (claims 10). See also column 13, line 20 to column 14, line 9). The combination of the CARBOPOL and the polyvinylpyrrolidone constitutes the hydrostatic couple of the instant application. The carbonate is the carbon dioxide precursor of the instant application. Rork teaches particulate formulation (column 8, lines 21-25) and the pharmaceutically active agents are present in amounts of from about 0.01% to about 75% of the core weight (column 8, lines 26-32). Rork does not disclose cross-linked polyvinylpyrrolidone. Ranitidine is one of the active agents in Rork (column 6, line 55). Conte discloses ranitidine composition that contains cross-linked polyvinylpyrrolidone (Example 4).

It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose....[T]he idea of combining them flows logically from their having been individually taught in the prior art.” In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). In the instant case, Conte and Rork disclose ranitidine containing composition. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to prepare the ranitidine composition of Rork. One having ordinary skill in the art would have been motivated to prepare a third composition comprising ranitidine, cross-linked

Art Unit: 1618

polyvinylpyrrolidone, polyvinylpyrrolidone and carbopol with the expectation that this third composition when administered would function as ranitidine dosage form for inhibiting gastric ulcer secretion in ulcer patients. "When the PTO shows a sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not." In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990).

***Response to Arguments***

6. Applicant's arguments filed 8/28/06 have been fully considered but they are not persuasive.

A. Applicant argues that there is no motivation to combine Rork with Conte because Rork discloses a tablet coated with material that is impermeable to water or to the selected product, drugs, polymer hydration modulating agents or to other compounds and that the impermeable material is insoluble in body fluids and non-erodible while Conte discloses multilayered tablet in which the outer layer is erodible and/or gellable and/or swellable hydrophilic polymers. Applicant thus concludes that the dosage forms Rork and Conte are mutually exclusive so that there would have been no motivation to combine or replace the dosage form of Rork with the dosage form taught by Conte.

**Response:**

The delivery device of Rork comprises a core that is made up of at least two layers (column 3, lines 33 and 34). In Conte, the second layer is hydrophilic and soluble and/or gellable and/or erodible and or swellable (column 7, lines 32 and 33). In the Conte reference, the second layer can be one of the possibilities listed above. Both dosage forms are orally administrable since the dosage forms in both references is a tablet and specifically layered tablet

Art Unit: 1618

and the one of the subject drug is ranitidine in both cases. Since Rork states that the tablet core comprises at least two layers, it stands to reason that more than two layers is contemplated. The difference between Rork and the claims is that Rork does not use a cross-linked polyvinylpyrrolidone in the composition and Rork is relied upon for using cross-linked polyvinylpyrrolidone with at least the same drug for oral administration by way of tablet dosage forms. Applicant's characterization that the two dosage forms are mutually exclusive appears to imply that the two dosage forms cannot occur or no two of the dosage forms can both be true dosage form or that the two dosage forms have nothing in common. However, both dosage forms are layered dosage forms for the delivery of say, ranitidine, via oral administration and the delivery systems therefore have commonalities.

Furthermore, applicant's arguments are directed to the individual references, and one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

B. Applicant states that improper hindsight reconstruction is adapted in the combination of Rork and Conte to arrive at the claimed invention.

**Response:**

7. In response to applicant's argument that the examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the



Art Unit: 1618

applicant's disclosure, such a reconstruction is proper. See *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971).

Applicant's disclosure had not been used as a guide to arriving at the obviousness rejection. Each of the two references discloses layered tablets for the oral delivery of at least ranitidine. Regarding the effect of cross-linked polyvinylpyrrolidone as a fast release polymer, it is noted that this polymer is the same polymer that is present in applicant's claimed delivery system. Since cross-linked polyvinylpyrrolidone is cross-linked polyvinylpyrrolidone, it stands to reason that the function or effect of the polymer would be the same in both the prior art and the claimed invention. Furthermore, Conte in column 3, lines 64-66 discloses that the dosage form exhibits high residence time in the stomach and or the first portion of the GI tract, which signifies delayed release. There is no disclosure of a burst or immediate release.

C. Applicant argues that the references taken alone or in combination does not provide zero order kinetics and that the swelling ability of the cross-linked polyvinylpyrrolidone would result in rapid hydration and concomitant expansion of the polymers so that the combination of Rork and Conte does not suggest all the elements of claims 1, 40 and 41.

**Response:**

An agent being released in a zero order or near zero order controlled release is a property/characteristic of the dosage. The cross-linked polyvinylpyrrolidone is the hydrostatic pressure modulating agent of the claims. The property or function of the cross-linked polyvinylpyrrolidone should not be different in the claimed delivery system and the delivery system of the prior art. The combination of Conte and Rork discloses all the elements of claims 1, 40 and 41 as described above in the rejection.

Art Unit: 1618

***Claim Rejections - 35 USC § 112***

8. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

9. Claim 42 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claim 42 is a new claim. Applicant states that the specification at pages 28-34 and Tables 1-7 provide support for claim 42. The Examples on pages 28-34 does not have ratio of hydrodynamic fluid imbibing polymer (CARBOPOL) to agent of interest from 1:1 to 9:1. The examples are calculated at 4 : 1, 3:1, 2.85:1 and 8.5:1. The specification as filed does not also provide support for hydrodynamic fluid imbibing polymer to hydrostatic pressure modulating agent ratio of from 35:1 to 167:1.

The above rejection may be overcome by removing the new matter from the claims.

No claim is allowed.

10. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period

Art Unit: 1618

will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Note: Applicant's attention is drawn to claim 26, which depends from canceled claim 2.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Blessing M. Fubara whose telephone number is (571) 272-0594. The examiner can normally be reached on 7 a.m. to 5:30 p.m. (Monday to Thursday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

BF

Blessing Fubara  
Patent Examiner  
Tech. Center 1600



MICHAEL G. HARTLEY  
SUPERVISORY PATENT EXAMINER